Omacetaxine (HHT*) CML Trials

ChemGenex

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing personalized medicines in the field of oncology. ChemGenex harnesses the power of genomics both to discover and validate novel targets and drug compounds, and in clinical trials to develop more individualized treatment outcomes. ChemGenex’s lead compound, omacetaxine mepesuccinate (formerly known as homoharringtonine or Ceflatonin^®), is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) to evaluate it for use as a single-agent treatment against drug-resistant disease, as well as for synergistic activity with the leading marketed compound. A second anticancer compound, amonafide dihydrochloride (Quinamed^®) is in phase 2 clinical development for various solid tumor cancers.

Stragen

With almost 20 years’ experience in the production and distribution of pharmaceuticals, Stragen Pharma is one of Europe’s leading private pharmaceutical companies. Stragen has a strong track record of fostering generic products through the European regulatory environment, and has a broad portfolio of products at market across a wide range of indications. Stragen’s strength in regulatory affairs is complemented by a successful distribution network across Europe that has enabled it to market products either directly or through long-term license agreement in specific territories.
Stragen’s strategic vision is to expand its generics product portfolio to include injectable, oral, and topical products and to grow a suite of original products for commercialization. The first of these is omacetaxine, which Stragen will commercialize (following regulatory authority approval) with its joint venture partner, ChemGenex Pharmaceuticals, within Europe.